Investigating MRI-Associated Biological Aspects of Racial Disparities in Prostate Cancer for African American and White Men.
health disparity
multi‐parametric MRI
prostate cancer
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
revised:
30
03
2024
received:
08
05
2023
accepted:
01
04
2024
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
Understanding the characteristics of multiparametric MRI (mpMRI) in patients from different racial/ethnic backgrounds is important for reducing the observed gaps in clinical outcomes. To investigate the diagnostic performance of mpMRI and quantitative MRI parameters of prostate cancer (PCa) in African American (AA) and matched White (W) men. Retrospective. One hundred twenty-nine patients (43 AA, 86 W) with histologically proven PCa who underwent mpMRI before radical prostatectomy. 3.0 T, T2-weighted turbo spin echo imaging, a single-shot spin-echo EPI sequence diffusion-weighted imaging, and a gradient echo sequence dynamic contrast-enhanced MRI with an ultrafast 3D spoiled gradient-echo sequence. The diagnostic performance of mpMRI in AA and W men was assessed using detection rates (DRs) and positive predictive values (PPVs) in zones defined by the PI-RADS v2.1 prostate sector map. Quantitative MRI parameters, including K Weighted Pearson's chi-square and Mann-Whitney U tests with a statistically significant level of 0.05 were used to examine differences in DR and PPV and to compare parameters between AA and matched W men, respectively. A total number of 264 PCa lesions were identified in the study cohort. The PPVs in the peripheral zone (PZ) and posterior prostate of mpMRI for csPCa lesions were significantly higher in AA men than in matched W men (87.8% vs. 68.1% in PZ, and 89.3% vs. 69.6% in posterior prostate). The K This study demonstrated race-related differences in the diagnostic performances and quantitative MRI measures of csPCa that were not reflected in age, PSA, and prostate volume. 3 TECHNICAL EFFICACY: Stage 2.
Sections du résumé
BACKGROUND
BACKGROUND
Understanding the characteristics of multiparametric MRI (mpMRI) in patients from different racial/ethnic backgrounds is important for reducing the observed gaps in clinical outcomes.
PURPOSE
OBJECTIVE
To investigate the diagnostic performance of mpMRI and quantitative MRI parameters of prostate cancer (PCa) in African American (AA) and matched White (W) men.
STUDY TYPE
METHODS
Retrospective.
SUBJECTS
METHODS
One hundred twenty-nine patients (43 AA, 86 W) with histologically proven PCa who underwent mpMRI before radical prostatectomy.
FIELD STRENGTH/SEQUENCE
UNASSIGNED
3.0 T, T2-weighted turbo spin echo imaging, a single-shot spin-echo EPI sequence diffusion-weighted imaging, and a gradient echo sequence dynamic contrast-enhanced MRI with an ultrafast 3D spoiled gradient-echo sequence.
ASSESSMENT
RESULTS
The diagnostic performance of mpMRI in AA and W men was assessed using detection rates (DRs) and positive predictive values (PPVs) in zones defined by the PI-RADS v2.1 prostate sector map. Quantitative MRI parameters, including K
STATISTICAL TESTS
METHODS
Weighted Pearson's chi-square and Mann-Whitney U tests with a statistically significant level of 0.05 were used to examine differences in DR and PPV and to compare parameters between AA and matched W men, respectively.
RESULTS
RESULTS
A total number of 264 PCa lesions were identified in the study cohort. The PPVs in the peripheral zone (PZ) and posterior prostate of mpMRI for csPCa lesions were significantly higher in AA men than in matched W men (87.8% vs. 68.1% in PZ, and 89.3% vs. 69.6% in posterior prostate). The K
DATA CONCLUSION
CONCLUSIONS
This study demonstrated race-related differences in the diagnostic performances and quantitative MRI measures of csPCa that were not reflected in age, PSA, and prostate volume.
EVIDENCE LEVEL
METHODS
3 TECHNICAL EFFICACY: Stage 2.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Division of Cancer Prevention, National Cancer Institute
ID : R01-CA248506
Organisme : National Cancer Research Institute
ID : R01-CA272702
Organisme : Integrated Diagnostics Program of the Departments of Radiological Sciences and Pathology in the UCLA David Geffen School of Medicine
Informations de copyright
© 2024 International Society for Magnetic Resonance in Medicine.
Références
Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet 2016;387:70‐82. https://doi.org/10.1016/s0140-6736(14)61947-4.
Riviere P, Luterstein E, Kumar A, et al. Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system. Cancer 2020;126:1683‐1690. https://doi.org/10.1002/cncr.32666.
Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity – United States, 2001‐2017. MMWR Morb Mortal Wkly Rep 2020;69:1473‐1480. https://doi.org/10.15585/mmwr.mm6941a1.
Borno H, George DJ, Schnipper LE, Cavalli F, Cerny T, Gillessen S. All men are created equal: Addressing disparities in prostate cancer care. Am Soc Clin Oncol Educ Book 2019;39:302‐308. https://doi.org/10.1200/edbk_238879.
Friedlander DF, Trinh QD, Krasnova A, et al. Racial disparity in delivering definitive therapy for intermediate/high‐risk localized prostate cancer: The impact of facility features and socioeconomic characteristics. Eur Urol 2018;73:445‐451. https://doi.org/10.1016/j.eururo.2017.07.023.
Ziehr DR, Mahal BA, Aizer AA, et al. Income inequality and treatment of African American men with high‐risk prostate cancer. Urol Oncol 2015;33:18.e7‐18.e13. https://doi.org/10.1016/j.urolonc.2014.09.005.
Bhardwaj A, Srivastava SK, Khan MA, et al. Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed) 2017;22:772‐782. https://doi.org/10.2741/4515.
Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African‐American and European‐American men. Cancer Res 2008;68:927‐936. https://doi.org/10.1158/0008-5472.Can-07-2608.
Smith ZL, Eggener SE, Murphy AB. African‐American prostate cancer disparities. Curr Urol Rep 2017;18:81. https://doi.org/10.1007/s11934-017-0724-5.
Craciunescu OI, Blackwell KL, Jones EL, et al. DCE‐MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: A pilot study. Int J Hyperthermia 2009;25:405‐415. https://doi.org/10.1080/02656730903022700.
Kim H, Folks KD, Guo L, et al. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast‐enhanced magnetic resonance imaging. Mol Imaging 2011;10:153‐167.
Mano R, Eastham J, Yossepowitch O. The very‐high‐risk prostate cancer: A contemporary update. Prostate Cancer Prostatic Dis 2016;19:340‐348. https://doi.org/10.1038/pcan.2016.40.
Yuan Q, Costa DN, Sénégas J, et al. Quantitative diffusion‐weighted imaging and dynamic contrast‐enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients. J Magn Reson Imaging 2017;45:908‐916. https://doi.org/10.1002/jmri.25391.
Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast‐enhanced endorectal MR imaging prior to radical prostatectomy: Experienced versus less experienced readers. Radiology 2005;237:541‐549. https://doi.org/10.1148/radiol.2372041724.
Abdalla I, Ray P, Ray V, Vaida F, Vijayakumar S. Comparison of serum prostate‐specific antigen levels and PSA density in African‐American, white, and Hispanic men without prostate cancer. Urology 1998;51:300‐305. https://doi.org/10.1016/S0090-4295(97)00617-1.
Klein EA, Patel AR. Risk factors for prostate cancer. Nat Clin Pract Urol 2009;6:87‐95. https://doi.org/10.1038/ncpuro1290.
Ibraheem A, Olopade OI, Huo D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer 2020;126(17):4013‐4022.
Azin A, Guidolin K, Chadi SA, Quereshy FA. Racial disparities in colon cancer survival: A propensity score matched analysis in the United States. Surgery 2022;171(4):873‐881.
Deebajah M, Keeley J, Park H, et al. A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate. Urol Oncol 2019;37(8):531.e1‐531.e5.
Henning GM, Vetter JM, Drake BF, et al. Diagnostic performance of prostate multiparametric magnetic resonance imaging in African‐American men. Urology 2019;134:181‐185.
Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer ‐ an ISUP consensus on contemporary grading. APMIS 2016;124:433‐435. https://doi.org/10.1111/apm.12533.
American College of Radiology. PI‐RADSTM prostate imaging reporting and data system. Amsterdam, Netherlands: Elsevier; 2019 Available from: https://www.acr.org/-/media/ACR/Files/RADS/Pi-RADS/PIRADS-V2-1.pdf.
Vajuvalli NN, Chikkemenahally DKK, Nayak KN, Bhosale MG, Geethanath S. The Tofts model in frequency domain: Fast and robust determination of pharmacokinetic maps for dynamic contrast enhancement MRI. Phys Med Biol 2016;61:8462‐8475. https://doi.org/10.1088/0031-9155/61/24/8462.
Parker GJ, Roberts C, Macdonald A, et al. Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI. Magn Reson Med 2006;56:993‐1000. https://doi.org/10.1002/mrm.21066.
Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast‐enhanced T(1)‐weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999;10:223‐232. https://doi.org/10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s.
Chao SL, Metens T, Lemort M. TumourMetrics: A comprehensive clinical solution for the standardization of DCE‐MRI analysis in research and routine use. Quant Imaging Med Surg 2017;7:496‐510. https://doi.org/10.21037/qims.2017.09.02.
van Leenders G, van der Kwast T, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 2020;44:e87‐e99. https://doi.org/10.1097/PAS.0000000000001497.
Jackson A, O'Connor JPB, Parker GJM, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast‐enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449‐3459.
QuickStats: Age‐adjusted death rates* from prostate cancer,† by race/ethnicity – National Vital Statistics System, United States, 1999–2017. MMWR Morb Mortal Wkly Rep 2019;68:531. https://doi.org/10.15585/mmwr.mm6823a4.
Kuhlmann PK, Chen M, Luu M, et al. Patient‐ and tumor‐level risk factors for MRI‐invisible prostate cancer. Prostate Cancer Prostatic Dis 2021;24:794‐801. https://doi.org/10.1038/s41391-021-00330-7.
Hötker AM, Mazaheri Y, Aras Ö, et al. Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast‐enhanced MRI. AJR Am J Roentgenol 2016;206:756‐763. https://doi.org/10.2214/ajr.15.14912.
Sung K. Modified MR dispersion imaging in prostate dynamic contrast‐enhanced MRI. J Magn Reson Imaging 2019;50:1307‐1317. https://doi.org/10.1002/jmri.26685.
Gaur S, Lay N, Harmon SA, et al. Can computer‐aided diagnosis assist in the identification of prostate cancer on prostate MRI? A multi‐center, multi‐reader investigation. Oncotarget 2018;9:33804‐33817. https://doi.org/10.18632/oncotarget.26100.
Wibulpolprasert P, Raman SS, Hsu W, et al. Influence of the location and zone of tumor in prostate cancer detection and localization on 3‐T multiparametric MRI based on PI‐RADS version 2. AJR Am J Roentgenol 2020;214:1101‐1111. https://doi.org/10.2214/AJR.19.21608.
Gulcehre C, Bengio Y. Knowledge matters: Importance of prior information for optimization. J Mach Learn Res 2016;17:1‐32. Available from: https://arxiv.org/abs/1301.4083.
Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012;61:1019‐1024.
D'Elia C, Cerruto MA, Cioffi A, Novella G, Cavalleri S, Artibani W. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy. Mol Clin Oncol 2014;2:1145‐1149. https://doi.org/10.3892/mco.2014.370.
Le JD, Tan N, Shkolyar E, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: Correlation with whole‐mount histopathology. Eur Urol 2015;67:569‐576.
Kim H. Variability in quantitative DCE‐MRI: Sources and solutions. J Nat Sci 2018;4(1):e484.
Kim H, Mousa M, Schexnailder P, et al. Portable perfusion phantom for quantitative DCE‐MRI of the abdomen. Med Phys 2017;44:5198‐5209. https://doi.org/10.1002/mp.12466.